{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-017520","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.985262+00:00","generated_at":"2026-06-05T13:39:15.970929+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"ImmuCell FY2023 net loss widens to $5.8M; Q4 sales up 30% but margin pressured","bullets":["Net loss $5.8M ($0.75 per share) in FY2023 vs $2.5M ($0.32) prior year.","Product sales $17.5M in FY2023, down 6% from $18.6M; Q4 sales $5.1M, up 30%.","Gross margin fell to 22% in FY2023 from 41% due to contamination events and write-offs.","EBITDA turned negative to ($2.6M) vs positive $350K in FY2022.","Cash dropped to <$1M from $5.8M; FDA response on Re-Tain expected by May 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-017520","json":"https://secwatch.observer/filing/0001213900-24-017520.json","markdown":"https://secwatch.observer/filing/0001213900-24-017520.md","text":"https://secwatch.observer/filing/0001213900-24-017520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/0001213900-24-017520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/ea0200797-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T13:39:15.970929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95dde54b37c95645f468f5ea6ab3dc3f4b26c357","claim":"IMMUCELL CORP /DE/ reported the three-month period ended December 31, 2023 results: revenue $5.1 million, net income Net loss was $1.1 million, EPS $0.15 per basic share.","evidence_excerpt":"Product sales increased by 30%, or $1.2 million, to $5.1 million during the three-month period ended December 31, 2023 compared to $3.9 million during the three-month period ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/0001213900-24-017520-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three-month period ended December 31, 2023"},{"label":"Revenue","value":"$5.1 million"},{"label":"Net income","value":"Net loss was $1.1 million"},{"label":"EPS","value":"$0.15 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c793aff87bd4f2be9b9d47e5c4f8f5221ff473e7","claim":"IMMUCELL CORP /DE/ reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On February 27, 2024 ImmuCell Corporation (the \"Company\") issued a press release announcing its unaudited financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/0001213900-24-017520-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f32e6a5e0deae02247f6b949e87a0589323cbb6f","claim":"IMMUCELL CORP /DE/ reported the year ended December 31, 2023 results: revenue $17.5 million, net income Net loss was $5.8 million, EPS $0.75 per basic share.","evidence_excerpt":"Product sales decreased by 6%, or $1.1 million, to $17.5 million during the year ended December 31, 2023 compared to $18.6 million during the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/0001213900-24-017520-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$17.5 million"},{"label":"Net income","value":"Net loss was $5.8 million"},{"label":"EPS","value":"$0.75 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}